Intravitreal bevacizumab therapy on an as-per-needed basis in subfoveal choroidal neovascularization secondary to pathological myopia: 2-year outcomes of a prospective case series

Retina

Volumn 31, Issue 9, 2011, Pages 1841-1847

  Iacono, Pierluigi ^a   Parodi, Maurizio Battaglia ^b   Papayannis, Alessandro ^b   Kontadakis, Stylianos ^b   Sheth, Saumil ^b   Bandello, Francesco ^b  

^a IRCCS FONDAZIONE BIETTI   (Italy)

^b VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

Author keywords

anti VEGF; intravitreal bevacizumab; pathologic myopia; subfoveal myopic choroidal neovascularization

Indexed keywords

BEVACIZUMAB;

ADULT; AGED; ARTICLE; CASE STUDY; CENTRAL MACULAR THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EYE EXAMINATION; FEMALE; FLUORESCENCE ANGIOGRAPHY; FOLLOW UP; HUMAN; MALE; MYOPIA; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; PROSPECTIVE STUDY; SUBRETINAL FLUID; SUBRETINAL NEOVASCULARIZATION; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; VISUAL ACUITY; VISUAL SYSTEM PARAMETERS;

ADULT; AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; MYOPIA, DEGENERATIVE; PROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 80053369084     PISSN: 0275004X     EISSN: 15392864     Source Type: Journal    
DOI: 10.1097/IAE.0b013e31821800a4     Document Type: Article

References (29)

1. Tokoro T. Criteria for diagnosis of pathologic myopia. In: Tokoro T, ed. Atlas of Posterior Fundus Changes in Pathlogic Myopia. New York, NY: Springer Verlag; 1998:1-2.
2. Grossniklaus HE, Green WR. Pathologic findings in pathologic myopia. Retina 1992;12:127-133.
3. Yoshida T, Ohno-Matsui K, Yasuzumi K, et al. Myopic choroidal neovascularization: A 10-year follow-up. Ophthalmology 2003;110:1297-1305.
4. Secretan M, Kuhn D, Soubrane G, et al. Long-term visual outcome of choroidal neovascularization in pathologic myopia: Natural history and laser treatment. Eur J Ophthalmology 1997;7:307-316.
5. Verteporfirin in Photodynamic Therapy (VIP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin: 1-year results of a randomized clinical trial-VIP report no.1. Ophthalmology 2001;108:841-852.
6. Blinder KJ, Blumenkranz MS, Bressler NM, et al. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia: 2-year results of a randomized clinical trial-VIP report no. 3. Ophthalmology 2003;110:667-673.
7. Kobayashi H, Kobayashi K. Radiotherapy for subfoveal neovascularization associated with pathological myopia: A pilot study. Br J Ophthalmol 2000;84:761-766.
8. Ruiz-Moreno JM, de la Vega C. Surgical removal of subfoveal choroidal neovascularization in highly myopic patients. Br J Ophthalmol 2001;85:1041-1043.
9. Hamelin N, Glacet-Bernard A, Brindeau C, et al. Surgical treatment of subfoveal neovascularization in myopia: Macular translocation versus surgical removal. Am J Ophthalmol 2002; 133:530-536.
10. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003;9:669-676.
11. Konstantinidis L, Mantel I, Pournaras JA, et al. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization. Graefes Arch Clin Exp Ophthalmol 2009; 247:311-318.
12. Sakaguchi H, Ikuno Y, Kamei M, et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007;91:161-165.
13. Ruiz-Moreno JM, Montero JA, Gomez-Ulla F, Ares S. Intravitreal bevacizumab to treat subfoveal choroidal neovascularisation in highly myopic eyes: 1-year outcome. Br J Ophthalmol 2009;93:448-451.
14. Chan WM, Lai TY, Chan KP, et al. Intravitreal bevacizumab (Avastin) for myopic choroidal neovascularisation: 1-year results of a prospective pilot study. Br J Ophthalmol 2009;93:150-154.
15. Gharbiya M, Allievi F, Mazzeo L, Gabrieli CB. Intravitreal bevacizumab treatment for choroidal neovascularization in pathologic myopia: 12-month results. Am J Ophthalmol 2009; 147:84-93.
16. Ikuno Y, Sayanagi K, Soga K, et al. Intravitreal bevacizumab for choroidal neovascularization attributable to pathological myopia: One-year results. Am J Ophthalmol 2009;147:94-100.
17. Hayashi K, Ohno-Matsui K, Shimada N, et al. Intravitreal bevacizumab on myopic choroidal neovascularization that was refractory to or had recurred after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2009;247:609-618.
18. Ruiz-Moreno JM, Gomez-Ulla F, Montero JA, et al. Intravitreous bevacizumab to treat subfoveal choroidal neovascularization in highly myopic eyes: Short term results. Eye 2009; 23:334-348.
19. Rensch F, Spandau UH, Schlichtenbrede F, et al. Intravitreal bevacizumab for myopic choroidal neovascularization. Ophthalmic Surg Lasers Imaging 2008;39:182-185.
20. Lai TY, Chan WM, Liu DT, Lam DS. Intravitreal ranibizumab for the primary treatment of choroidal neovascularization secondary to pathologic myopia. Retina 2009;29:750-756.
21. Silva RM, Ruiz-Moreno JM, Nascimento J, et al. Short term efficacy and safety of intravitreal ranibizumab for myopic choroidal neovascularization. Retina 2008;28:1117-1123.
22. Voykov B, Gelisken F, Inhoffen W, et al. Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years? Graefes Arch Clin Exp Ophthalmol 2010;248:543-550.
23. Ikuno Y, Nagai Y, Matsuda S, et al. Two-year visual results for older Asian women treated with photodynamic therapy or bevacizumab for myopic choroidal neovascularization. Am J Ophthalmol 2010;149:140-146.
24. Lalloum F, Souied EH, Bastuji-Garin S, et al. Intravitreal ranibizumab for choroidal neovascularization complicating pathologic myopia. Retina 2010;30:399-406.
25. Ruiz-Moreno JM, Montero JA. Intravitreal bevacizumab to treat myopic choroidal neovascularization: 2-year outcome. Graefes Arch Clin Exp Ophthalmol 2010;248:937-941.
26. Axer-Siegel R, Ehrlich R, Weinberger D, et al. Photodynamic therapy of subfoveal choroidal neovascularization in high myopia in a clinical setting: Visual outcome in relation to age at treatment. Am J Ophthalmol 2004;138:602-607.
27. Ergun E, Heinzl H, Stur M. Prognostic factors influencing visual outcome of photodynamic therapy for subfoveal choroidal neovascularization in pathologic myopia. Am J Ophthalmol 2004;138:434-438.
28. Parodi MB, Iacono P, Papayannis A, et al. Laser photocoagulation, photodynamic therapy, and intravitreal bevacizumab for the treatment of juxtafoveal choroidal neovascularization secondary to pathologic myopia. Arch Ophthalmol 2010;128: 437-442.
29. Baba T, Kubota-Taniai M, Kitahashi M, et al. Two-year comparison of photodynamic therapy and intravitreal bevacizumab for treatment of myopic choroidal neovascularisation. Br J Ophthalmol 2010;94:864-870.